Loading...
Back to narrative

Update shared on29 Jul 2025

Fair value Decreased 6.60%
AnalystConsensusTarget's Fair Value
SEK 238.00
13.8% undervalued intrinsic discount
27 Aug
SEK 205.05
Loading
1Y
13.0%
7D
-2.7%

The downward revision in Mycronic's analyst price target reflects notably softer outlooks for both revenue growth and net profit margin, resulting in a reduced fair value from SEK245.73 to SEK229.50.


What's in the News


  • Mycronic increased its 2025 net sales guidance to SEK 7.5 billion, restoring its original outlook.
  • The company implemented a 2:1 stock split, raising its share count to 195,833,018.
  • Amendments to the articles of association were approved, adjusting limits on share numbers and authorizing the share split.
  • An ordinary dividend of SEK 5.50 per share was approved at the AGM.

Valuation Changes


Summary of Valuation Changes for Mycronic

  • The Consensus Analyst Price Target has fallen from SEK245.73 to SEK229.50.
  • The Consensus Revenue Growth forecasts for Mycronic has significantly fallen from 3.7% per annum to 1.3% per annum.
  • The Net Profit Margin for Mycronic has fallen from 22.35% to 21.16%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.